• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Rac­ing af­ter the lead­ers, Eli Lil­ly's mi­graine drug clears an­oth­er piv­otal study

6 years ago
Pharma

Close to a decade af­ter Eli Lil­ly killed it, Jef­frey Blue­stone's 'break­through' drug is back and be­ing steered to the ...

6 years ago
R&D
FDA+

CMS pre­scribes pay­ment fix to re­sus­ci­tate US an­tibi­ot­ic in­dus­try

6 years ago
FDA+

Roche scores a no­table PhI­II suc­cess with Tecen­triq com­bo in blad­der can­cer, but is this an­oth­er case of too lit­tle ...

6 years ago
R&D
Pharma

Dai­ichi Sankyo scores land­mark FDA OK for rare tu­mor drug — al­beit with re­stric­tions

6 years ago
Pharma

Join­ing Chang and Bellde­grun, Rafael Ama­do takes a lead­ing R&D post in the next big cell ther­a­py rev­o­lu­tion

6 years ago
People
Cell/Gene Tx

Gly­coMimet­ics shares crash af­ter Pfiz­er team dis­miss­es their lead drug as a PhI­II fail­ure

6 years ago
R&D

David Apelian to steer TCR play at Pitt spin­out; Third Rock scoops Il­lu­mi­na ex­ec as CEO of can­cer de­tec­tion up­start

6 years ago
Peer Review

Backed by No­vo and Or­biMed, Thier­ry Abri­b­at hauls in $75M for biotech #3 — a transat­lantic up­start fo­cused on rare ...

6 years ago
People
Startups

Move over, Hong Kong: Shang­hai’s new tech board sees fer­vent de­mand for maid­en biotech IPO

6 years ago
Financing
China

Salk sci­en­tists cre­ate the world’s first hu­man/mon­key chimeras in Chi­na — cue the con­tro­ver­sy

6 years ago
R&D

Ko­re­an biotech sees shares blitzed as its on­colyt­ic virus/Nex­avar com­bo fiz­zles in liv­er can­cer

6 years ago
R&D

Bio­Marin ex­ecs make their case for he­mo­phil­ia gene ther­a­py as fret­ful an­a­lysts start to hedge their bets

6 years ago
R&D

At new­ly rechris­tened Rakuten Med­ical, Japan­ese bil­lion­aire Mik­i­tani ups the ante with an­oth­er megaround

6 years ago
Financing

Adri­an Hay­day re­futes chal­lenge on in­flu­en­tial au­toan­ti­body pa­per by Karolin­s­ka sci­en­tists

6 years ago
Discovery

Am­i­cus touts lat­est set of gene ther­a­py da­ta; No­vo Nordisk ex­pands dis­cov­ery deal for di­a­betes

6 years ago
News Briefing

Jump­ing in­to grow­ing queue of buy­ers, Ver­tex chief tar­gets a slate of new and 'larg­er' deals ahead

6 years ago
People
Deals

PD-L1, CD47 and now CD24? Star Stan­ford I/O sci­en­tist Irv Weiss­man points to a ‘ma­jor’ new can­cer tar­get

6 years ago
People
Discovery

FDA-EMA work­shop dis­cuss­es qual­i­ty chal­lenges for PRIME, break­through ther­a­pies

6 years ago
FDA+

Adap­ti­m­mune R&D chief Ama­do hits the ex­it amid a top-lev­el shake­up as new CEO tries to re­vive ebbing en­thu­si­asm

6 years ago
People

Fresh de­lay for $4.3B Roche/Spark deal trig­gers an­a­lyst con­cerns about gene ther­a­py M&A

6 years ago
Deals

Still trail­ing far be­hind a block­buster ri­val, No­var­tis gath­ers an­oth­er round of pos­i­tive sur­vival da­ta for Kisqali

6 years ago
R&D

Arie Bellde­grun and the crew at Vi­da reap a $600M har­vest for fund II — and they've got LA in their sights

6 years ago
Financing

At­lantic Health­care's drug fails late-stage test; Trans­late Bio breaks out ear­ly CF da­ta

6 years ago
News Briefing
First page Previous page 911912913914915916917 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.